CSE: WBIO
Last: 0.71
Change: 0
Vol: 119,250

Berubicin

Technology Overview

New Approach to Glioblastoma Treatment Addressing the Critical Unmet Medical Need.

Overview

Berubicin is an exciting new drug that is one of the first anthracyclines proven to cross the blood-brain barrier (BBB) and able to reach brain tumors. This discovery can potentially extend the clinical use of anthracyclines to brain tumors, specifically GBM.

Clinic Development

Berubicin’s Phase I clinical trial, the first time it was tested in humans, yielded very promising results with 44% of the patients showing a clinical response. In addition, Berubicin has shown evidence of improved overall survival in a patient population that currently has a dismal median survival rate of only 14.6 months from diagnosis.

Clinic Development

Grants / Funding

This project is co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Program 2014-2020, Sectoral Programme InnoNeuroPharm, Priority Axis I: Support R&D carried out by enterprises, Measure 1.2: Sectoral R&D Programmes, implemented under National Center for Research and Development.

Co-financing of the project from the EU: 22 033 066,00 PLN

Total Project value: PLN 33 306 215,00
Contribution of the European Union Funds: PLN 22 033 066,00

Partners

Regulatory

Berubicin has previously received an Orphan Drug designation in the US, which provides seven years of marketing exclusivity.

Partners, Affiliations & License

Reata Pharmaceuticals (Nasdaq: RETA) - $3 Billion- dollar Nasdaq listed company

Houston Pharmaceuticals

CNS Pharmaceuticals – co-development partner

WPD owns the exclusive license to 30 countries in Europe and Asia and also Poland and Russia.

This project is co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Program 2014-2020, Sectoral Programme InnoNeuroPharm, Priority Axis I: Support R&D carried out by enterprises, Measure 1.2: Sectoral R&D Programmes, implemented under National Center for Research and Development.

Co-financing of the project from the EU: 22 033 066,00 PLN

Subscribe to our Newsletter